During the corresponding time, Neurocrine Biosciences Inc recorded a revenue increase by 39.49 % year on year, sequentially revenue grew by 17.74 %. While revenue at the Neurocrine Biosciences Inc 's corporate clients
Neurocrine Biosciences Inc's Comment on Sales, Marketing and Customers
The company’s customers include select specialty pharmacy providers, wholesale distributors, and specialty distributors. CRENESSITY is distributed in the U.S. exclusively through a single specialty pharmacy provider due to its focus on rare diseases. Packaging, warehousing, and shipment are managed by third-party logistics providers. The commercial sales force consists of approximately 600 professionals specializing in neurology, psychiatry, long-term care, and rare diseases. Plans are in place to expand the INGREZZA and CRENESSITY sales teams to increase engagement with prescribers in community and institutional settings and to support growth in endocrinology and rare disease sectors. The company is also preparing for upcoming product launches targeting major depressive disorder and schizophrenia. Manufacturing and supply of INGREZZA, CRENESSITY, and product candidates are conducted through third-party manufacturers and suppliers under long-term agreements to ensure adequate supply. The company maintains compliance with current Good Manufacturing Practice (cGMP) requirements through oversight of its third-party partners.
Neurocrine Biosciences Inc’s Comment on Sales, Marketing and Customers
The company’s customers include select specialty pharmacy providers, wholesale distributors, and specialty distributors. CRENESSITY is distributed in the U.S. exclusively through a single specialty pharmacy provider due to its focus on rare diseases. Packaging, warehousing, and shipment are managed by third-party logistics providers. The commercial sales force consists of approximately 600 professionals specializing in neurology, psychiatry, long-term care, and rare diseases. Plans are in place to expand the INGREZZA and CRENESSITY sales teams to increase engagement with prescribers in community and institutional settings and to support growth in endocrinology and rare disease sectors. The company is also preparing for upcoming product launches targeting major depressive disorder and schizophrenia. Manufacturing and supply of INGREZZA, CRENESSITY, and product candidates are conducted through third-party manufacturers and suppliers under long-term agreements to ensure adequate supply. The company maintains compliance with current Good Manufacturing Practice (cGMP) requirements through oversight of its third-party partners.
Sources:
Neurocrine Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Neurocrine Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Neurocrine Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
184.08 %